Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Ref Type | |||||||||||||
| PMID | (39141861) | ||||||||||||
| Authors | Cupit-Link M, Hagiwara K, Nagy M, Koo SC, Orr BA, Ruppin E, Easton J, Zhang J, Federico SM | ||||||||||||
| Title | Response to PARP Inhibition in BARD1-Mutated Refractory Neuroblastoma. | ||||||||||||
|
|||||||||||||
| URL | |||||||||||||
| Abstract Text | |||||||||||||
| Molecular Profile | Treatment Approach |
|---|
| Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
|---|
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|
| Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
|---|
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BARD1 Y180fs BARD1 loss | neuroblastoma | predicted - sensitive | Irinotecan + Talazoparib | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Talzenna (talazoparib) and Camptosar (irinotecan) resulted in a complete response in a pediatric patient with high-risk relapsed/refractory neuroblastoma harboring germline BARD1 Y180fs and somatic Bard1 loss (PMID: 39141861). | 39141861 |